7 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 3 Not applicable, 3 Phase 1, 2 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 2, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow this drug Literature Review of Deuterium Oxide trials Research Report on Deuterium Oxide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Insulin Lowering on Lipogenesis Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70% - Hyperinsulinemia, Insulin Resistance | Phase 1 | Recruiting | Columbia University | 25 | 2026-07-01 | 2026-07-06 |
| Implementation and Validation of an Analytical Protocol for Measuring de Novo Lipogenesis in the Liver Using Stable Isotopes Deuterium oxide - De Novo Lipogenesis (DNL), Lipid Metabolism | Not applicable | Completed | KU Leuven | 10 | 2025-08-25 | 2026-08-03 |
| Immunology of Ebola Vaccine Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP), Deuterium Labeled Water - Ebola Virus Disease | Phase 2 | Active not recruiting | Emory University | 30 | 2024-08-06 | 2026-01-22 |
| Glycemic Effect of Diazoxide in NAFLD Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo - Hyperinsulinemia, Insulin Resistance | Phase 1 | Completed | Columbia University | 22 | 2023-08-01 | 2026-09-30 |
| D2O Dosing Strategies to Assess Muscle Protein Synthesis Deuterium Oxide (D2O) Dose - Hypertrophy | Not applicable | Withdrawn | McMaster University | 2020-05-01 | 2023-03-15 | |
| Concurrent Assessment of Skeletal Muscle Mass and Synthesis/Breakdown in Old Age D3-Creatine, Deuterium Oxide, D3-3-methylhistidine - Sarcopenia, Muscle Atrophy | Completed | University of Nottingham | 37 | 2016-06-07 | 2020-03-25 | |
| Cold Induced Changes in White Adipose Fat biopsy, Propranolol and fat biopsy, heavy water and fat biopsy - Obese, Normal Body Weight | Early Phase 1 | Completed | Philip Kern | 26 | 2016-03-01 | 2020-02-07 |
| Tanita BIA System Validation Body Measurements, Body Composition and Circumference measurements, Whole Body DXA scan - Body Composition, Circumference Measurements | Completed | Pennington Biomedical Research Center | 150 | 2014-01-01 | 2017-05-05 | |
| Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL Heavy Water (2H2O), PCI-32765 - Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 30 | 2012-12-17 | 2020-02-24 |
| Feasibility Study: Heavy Water Tissue Labeling Protocol Ulthera® System Treatment, Heavy Water - Skin Laxity | Not applicable | Completed | Ulthera, Inc | 2 | 2012-08-01 | 2017-12-11 |
| Metabolism of Lipids in Advanced Cancer Blood draws, Oral administration of stable isotope (deuterium), Metabolic rate testing - Lung Neoplasms, Cachexia | Terminated | AHS Cancer Control Alberta | 12 | 2009-10-01 | 2016-02-26 |
Prediabetic State (3) · Hyperinsulinism (2) · Insulin Resistance (2) · Non-alcoholic Fatty Liver Disease (2) · Obesity (2) · Cachexia (1) · Cutis Laxa (1) · Hemorrhagic Fever, Ebola (1) · Hypertrophy (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Metabolic Syndrome (1) · Muscular Atrophy (1) · Sarcopenia (1)
Columbia University (2) · AHS Cancer Control Alberta (1) · Emory University (1) · KU Leuven (1) · M.D. Anderson Cancer Center (1) · McMaster University (1) · Pennington Biomedical Research Center (1) · Philip Kern (1) · Ulthera, Inc (1) · University of Nottingham (1)
United States (7) · Belgium (1) · Canada (1) · United Kingdom (1)
Joshua R Cook, MD, PhD (2) · Ali Ellebedy, PhD (1) · Gordon Sasaki, MD (1) · Jan A. Burger, MD (1) · Nadine Rouphael, MD (1) · Philip Kern, MD (1) · Steven Heymsfield, MD (1) · Stuart M Phillips, Ph.D. (1) · Vera Mazurak, PhD (1)
PMID 28138560, PMID 30089732, PMID 35894077, PMID 39441901
K12DK133995 (1), K23DK140614 (1), R01DK107646 (1)